Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences' stock has experienced significant volatility and a notable decline over the past year. The share price decreased by 76.75% from November 25, 2024, to November 24, 2025, and has fallen by approximately 21.68% over the last six months, reaching a 52-week low of $1.525. Key events include securing $4 million in financing, reporting third-quarter 2025 financial results, and receiving positive written responses from the FDA regarding PF614 manufacturing plans in November 2025. In October 2025, the company released symposium highlights from PAINWeek 2025. August 2025 saw the reporting of second-quarter financial results and updates on programs, including the initiation of a pivotal Phase 3 trial for PF614 and the completion of enrollment for Part 2 of the PF614-MPAR-102 study. In July 2025, the company received positive feedback from the FDA regarding PF614-MPAR, confirming its eligibility for a streamlined 505(b)(2) regulatory pathway. In late May 2025, the Phase 3 trial for PF614 was officially launched. In April 2025, Part 1 of the clinical trial for PF614-MPAR was concluded, and approximately $1.1 million was raised through a stock sale to fund the development of its TAAP™ and MPAR® programs.

There is no information available regarding demand seasonality for Ensysce Biosciences, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by medical need and prescription rates rather than typical seasonal consumer patterns.

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative solutions for severe pain relief while addressing opioid misuse, abuse, and overdose. The company operates in the Health Technology sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. Ensysce Biosciences' pipeline is built upon two proprietary drug platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). Major products and candidates include PF614, PF614-MPAR, PF8001, PF8026, and PF9001.

Ensysce Biosciences, Inc. is headquartered in La Jolla, California, United States. Its primary focus is on drug development and regulatory processes, with its current operational and market reach predominantly within the United States.

No specific events directly impacting Ensysce Biosciences, Inc.'s brand reputation in the past year were found. The company's core mission to develop safer prescription opioids that reduce misuse, abuse, and overdose could be viewed positively. The FDA's "Fast Track" and "Breakthrough Therapy" designations for its technologies also contribute to a perception of innovation and potential impact.

The ownership structure of Ensysce Biosciences is a mix of institutional, insider, and individual investors. Institutional shareholders hold approximately 9.85% to 11.85% of the company's stock, with major holders including Perceptive Advisors Llc and Adage Capital Partners Gp, L.l.c. Insiders hold a significant portion of the company, with William H. Chang being the largest individual shareholder, owning 73.30% of the company. Public companies and individual investors collectively own approximately 90.60% of the stock.